Related Experiment Video

Updated: Sep 15, 2026

In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

Inhibitory effects of clonidine on bronchospasm induced in guinea-pigs by vagal stimulation or antigen challenge

R G Andersson, A Fügner, B R Lindgren

    European Journal of Pharmacology
    |April 16, 1986
    PubMed

    More Related Videos

    Murine Model of Allergen Induced Asthma08:05

    Murine Model of Allergen Induced Asthma

    Published on: May 14, 2012

    Methods for Detecting Cough and Airway Inflammation in Mice04:33

    Methods for Detecting Cough and Airway Inflammation in Mice

    Published on: August 2, 2024

    Related Concept Videos

    Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

    Direct-Acting Cholinergic Agonists: Pharmacological Actions

    Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
    Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

    Direct-Acting Cholinergic Agonists: Therapeutic Uses

    Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
    Cholinergic Antagonists: Pharmacological Actions01:28

    Cholinergic Antagonists: Pharmacological Actions

    Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
    Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
    Cholinergic Antagonists: Therapeutic Uses01:26

    Cholinergic Antagonists: Therapeutic Uses

    Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
    Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
    Drugs Acting on Autonomic Ganglia: Stimulants01:23

    Drugs Acting on Autonomic Ganglia: Stimulants


    Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
    Drugs Acting on Autonomic Ganglia: Blockers01:28

    Drugs Acting on Autonomic Ganglia: Blockers

    Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups: